诺诚健华2025年第一季度收入达3.8亿元,同比增长129.9%,主要得益于奥布替尼销售额增长。GSK因II期肺癌试验未达预期而终止TIGIT抗体belrestotug的研发。百济神州向全资子公司BGNC2发行1.33亿股用于股权激励。此外,汉密顿生物、信中医药、香雪生命、艾美疫苗及康弘药业等多家公司分别获得针对卵巢早衰、帕金森病、晚期胃癌、带状疱疹以及产后抑郁症的新药临床许可。这些进展反映了...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.